Dr. Launa Aspeslet discusses team collaboration required to develop voclosporin in Alberta


Share this:

In our latest video interview, Dr. Launa Aspeslet talks about the strength of the life sciences sector in Alberta, as well as the team collaboration required to develop voclosporin, the first oral medication for lupus nephritis that was recently approved by the FDA.

Dr. Aspeslet is now the CEO of Translational Research in Oncology (TRIO) as well as Chair of the Board of Directors at Applied Pharmaceutical Innovation (API). She did her undergraduate degree in Chemistry at the University of Lethbridge, and her PhD in Pharmaceutical Sciences at the University of Alberta.

We are proud to work with partners across the province to transform the life sciences in Alberta and beyond.

Video by Hoopla Media